Rhode Island Substance Abuse Record Privacy Laws: Your Rights and Provider Obligations

Confidentiality of Substance Abuse Records

Rhode Island substance abuse record privacy laws work alongside robust federal protections to keep your treatment information confidential. At the federal level, 42 C.F.R. Part 2 and 42 U.S.C. § 290dd-2 set strict rules for Substance Use Disorder Confidentiality, generally requiring your written consent before a program discloses any record that identifies you as having a substance use disorder or receiving related services.

State law reinforces these protections. Rhode Island Gen. Laws § 40.1-5-26 (often mis-cited as § 40-1-5-26) limits disclosure of behavioral health records and requires that releases follow state and federal confidentiality rules. These safeguards apply to providers, health systems, and any recipient of protected records, including billing vendors and care coordinators who handle your information.

Key points to remember about covered records and programs:

• Covered records include clinical notes, diagnosis codes, intake or discharge summaries, and any data that could identify you as receiving SUD services.
• Part 2 programs (and recipients of Part 2 records) must comply with redisclosure restrictions; information cannot be used in legal proceedings against you without a specific court order.
• HIPAA may also apply, but where Part 2 is stricter, Part 2 controls. References to 42 U.S.C. § 290dd and 42 U.S.C. § 290ii reflect related federal patient protections that complement privacy rules.

Disclosure for Research Purposes

Substance abuse records can be used in research only under carefully controlled conditions. Under 42 C.F.R. Part 2, disclosure to qualified personnel is permitted for scientific research, management audits, financial audits, or program evaluation when privacy safeguards are in place and re-identification is prohibited unless you have expressly consented.

Acceptable research pathways typically include: documented Institutional Review Board or Privacy Board approvals; de-identification that removes direct and indirect identifiers; or limited data sets coupled with data use agreements that bar re-identification and redisclosure. For public health monitoring or historical program evaluation—such as analyses based on the legacy Drug Abuse Reporting System—data must be aggregated or de-identified to prevent identification of individual patients.

If you do provide written consent, it must meet Part 2’s content requirements and specify the research purpose, the information to be shared, and the recipient. Providers should maintain disclosure logs and apply the “minimum necessary” principle whenever applicable to research requests.

Breach of Confidentiality Penalties

Unauthorized access, use, or disclosure of substance abuse records can trigger serious consequences. Under federal law, violations of 42 C.F.R. Part 2 and 42 U.S.C. § 290dd-2 may lead to civil monetary penalties and, in egregious cases, criminal liability. Breaches can also invite corrective action plans, audits, and loss of funding or contracts for noncompliant programs.

Rhode Island law adds state-level enforcement. Unlawful disclosures can result in civil penalties, injunctive relief, and professional discipline. Organizations may face reputational harm and mandatory notice obligations. Timely investigation, patient notification where required, and documented remediation are essential to limit exposure.

Federal and State Regulatory Compliance

Providers must harmonize multiple legal regimes. 42 C.F.R. Part 2 governs SUD records; HIPAA governs broader health information; and Rhode Island confidentiality statutes control behavioral health records. When Part 2 applies, its stricter redisclosure and consent rules take precedence. Federal protections like 42 U.S.C. § 290ii (relating to patient safety in certain federally funded settings) complement these privacy obligations.

Practical compliance expectations include:

• Data segmentation or “tagging” of Part 2 records in your EHR so protected information is not disclosed improperly.
• Use of Qualified Service Organization Agreements for vendors handling SUD data, and Business Associate Agreements where HIPAA applies.
• Standardized “Prohibition on Redisclosure” notices when sharing Part 2 information.
• Workforce training, role-based access controls, and consistent auditing of disclosures.
• Clear procedures for court orders, law enforcement requests, medical emergencies, and patient safety concerns.

Rhode Island Data Privacy Laws Overview

The Rhode Island Data Transparency and Privacy Protection Act is now in effect (January 1, 2026). It grants consumers rights to access, correct, delete, and opt out of certain data processing, with heightened safeguards for sensitive data such as health information. While data subject to HIPAA or 42 C.F.R. Part 2 may be exempt from portions of this consumer law, not all information a provider or app collects is automatically exempt.

What this means for you and your providers:

• You can expect more transparent notices about what data is collected and why, including on patient portals and mobile apps.
• Providers and their vendors should honor authenticated consumer requests and document how they handle sensitive data.
• Health systems should map where Part 2–protected data sits versus other consumer data to ensure correct application of exemptions and rights.

Patient Consent and Disclosure Procedures

Effective consent is the cornerstone of lawful disclosure. A Part 2–compliant consent should clearly identify you, describe the specific information to be released, name the recipient(s), state the purpose, set an expiration, and explain your right to revoke. For treatment, payment, and health care operations, you may authorize a broader, ongoing consent that remains in effect until you revoke it in writing.

Providers should follow a consistent workflow:

• Confirm whether the record is Part 2–protected and whether HIPAA or state law also applies.
• Use the correct consent form and include the “Prohibition on Redisclosure” statement with any release.
• Disclose only what is necessary for the stated purpose; log the disclosure as required by policy.
• For research, verify IRB/Privacy Board approvals or obtain patient consent that meets Part 2 standards.
• For medical emergencies, disclose the minimum necessary to treat the emergency and document the circumstances promptly.
• For legal demands, require a Part 2–specific court order; a subpoena alone is not sufficient.

Conclusion

In Rhode Island, substance abuse records receive some of the strongest privacy protections in the country. By centering 42 C.F.R. Part 2, honoring state confidentiality laws, and using clear, revocable consent, you and your providers can support effective care coordination while safeguarding your rights. References such as 42 U.S.C. § 290dd, 42 U.S.C. § 290ii, Rhode Island Gen. Laws § 40.1-5-26, and the Rhode Island Data Transparency and Privacy Protection Act frame these obligations.

FAQs.

What rights do patients have regarding substance abuse record confidentiality?

You have the right to keep your SUD treatment information private, to decide who receives it through written consent, and to revoke that consent. Your records generally cannot be used against you in legal proceedings without a specific court order. You can also request restrictions on certain disclosures and expect clear notices that bar redisclosure by recipients.

How can substance abuse records be legally disclosed for treatment or research?

For treatment, payment, and health care operations, you can provide written consent that authorizes ongoing disclosures until you revoke it. For research, records may be shared only with your consent or under strict safeguards—such as IRB-approved protocols, de-identification, or data use agreements—while honoring Part 2’s prohibition on redisclosure and patient re-identification.

What are the penalties for breaching substance abuse record confidentiality?

Violations can lead to federal civil monetary penalties, potential criminal liability in serious cases, state-level enforcement actions, and professional discipline. Organizations may face audits, corrective action, and reputational harm. Prompt investigation, required notifications, and remediation are critical after any breach.

How do federal and Rhode Island laws protect substance abuse patient information?

Federal law—principally 42 C.F.R. Part 2 and 42 U.S.C. § 290dd-2—requires consent for most disclosures, limits redisclosure, and bars use of records against you without a court order. Rhode Island law (including behavioral health confidentiality statutes and the Rhode Island Data Transparency and Privacy Protection Act) complements these rules by tightening state-level privacy controls and enhancing transparency and consumer rights.